Auna (AUNA) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
3 Dec, 2025Executive summary
Achieved 20.1% FXN Adjusted EBITDA growth for FY24, meeting all 2024 milestones and delivering positive net income for the year and four consecutive quarters.
Strong performance in Peru and Mexico, with Peru leading growth and Mexico benefiting from high-complexity services and strategic pricing; Colombia showed resilience but faced regulatory and payer challenges.
Leverage ratio improved to 3.6x, progressing toward a sub-3.0x target, with continued deleveraging and strengthened balance sheet.
Net income improved to S/124 million in FY24 from a loss of S/214 million in FY23, with robust free cash flow and cash position up 18% sequentially.
Expanded Board with two new independent directors, enhancing governance and diversity.
Financial highlights
FY24 revenue reached S/4,386 million, up 13% YoY (+12% FXN); 4Q24 revenue S/1,063 million, up 4% YoY (+11% FXN).
FY24 Adjusted EBITDA S/993 million, up 20% YoY (+20.1% FXN); 4Q24 Adjusted EBITDA S/254 million, up 19% YoY (+28% FXN).
Adjusted EBITDA margin improved to 22.6% for FY24 (+1.4 p.p. YoY) and 23.9% for 4Q24 (+3.1 p.p. YoY).
Adjusted Net Income for FY24 was S/146 million (Adjusted EPS S/1.97); 4Q24 Adjusted Net Income S/36 million (Adjusted EPS S/0.47).
Cash position at year-end was S/236 million, up 18% sequentially; free cash flow for 2024 was S/432 million.
Outlook and guidance
Internal goal remains 20% FXN Adjusted EBITDA growth for 2025, but formal guidance is withheld due to Colombia's regulatory and payer uncertainties.
Peru expected to continue stable growth; Mexico to focus on operational efficiencies, high-complexity services, and access expansion.
Colombia outlook remains cautious, focusing on cash flow, payer diversification, and adapting to regulatory changes.
Medium-term target to reduce leverage to 3x net debt/EBITDA, with further debt reduction planned as excess cash flow is expected.
Latest events from Auna
- FY25 saw strong cash flow, Peru and Colombia growth, and a 12% FXN growth target for 2026.AUNA
Q4 202511 Mar 2026 - Adjusted EBITDA up 31% and revenue up 18% year-over-year, with leverage ratio at 4.13x.AUNA
Q2 202423 Jan 2026 - Adjusted EBITDA up 23% YoY, leverage ratio at 3.7x, and OncoMexico pilot advancing.AUNA
Q3 202413 Jan 2026 - Healthcare group targets $1B NYSE offering to expand Latin American operations.AUNA
Registration Filing16 Dec 2025 - Healthcare group seeks up to $1B in NYSE-listed shares to fund growth in Latin America.AUNA
Registration Filing16 Dec 2025 - Peru's growth offset Mexico and Colombia's declines, sustaining profitability and stable leverage.AUNA
Q1 202526 Nov 2025 - Adjusted EBITDA up 5% FXN YoY; net income surged; leverage steady amid FX headwinds.AUNA
Q2 202523 Nov 2025 - Peru and Colombia grew, Mexico declined; leverage stable, refinancing done, Mexico recovery in 2026.AUNA
Q3 202521 Nov 2025